Felzartamab for kidney transplant patients with inflammation
Treatments studied
Part of Kidney & urinary clinical trials.
This trial tests a drug called felzartamab to see if it can help people who have a type of kidney inflammation after a transplant, even without donor-specific antibodies. It might offer a new treatment option for those who are not getting better on their own.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a kidney transplant at least 6 months ago
- A recent kidney biopsy shows a certain level of inflammation (called MVI) without signs of rejection by your immune cells
- You do not have certain antibodies that attack the donor kidney (called donor-specific antibodies)
- You have not received certain treatments for rejection in the last 3 months, or if you did, you waited at least 6 weeks after stopping them to have a biopsy
- Your kidney function is stable and not rapidly getting worse
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks the long-term safety of felzartamab for people who have had a kidney transplant and are dealing with antibody-mediated rejection or signs of inflammation in the kidney. It's for those who were already in a previous study and took at least one dose of felzartamab.
This study tests a new medicine called mezagitamab for people whose kidney transplant is being rejected by their immune system (a condition called antibody-mediated rejection). The goal is to see if it can help stop the rejection and protect the transplanted kidney.
This study tests a new drug called Felzartamab (given as an infusion) for people with IgA nephropathy (IgAN), a kidney disease. The goal is to see if it can reduce protein leaking into urine and protect kidney function.
This study tests whether felzartamab, given as an infusion, can help treat primary membranous nephropathy (a kidney disease causing protein in the urine and swelling). It may reduce protein loss and improve kidney function compared to standard care alone.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
Hear when a new Microvascular Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.